A variety of functional assays are available for agonist or antagonist screening of G protein-coupled receptors (GPCRs), but it is a priori not predictable which assay is the most suitable to identify agonists or antagonists of GPCRs with therapeutic value in humans. More specifically, it is not known how a given set of GPCR agonists compares in different functional assays with respect to potency and efficacy and whether the level of the signaling cascade that is analyzed has any impact on the detection of agonistic responses. To address this question, the authors used the recently cloned human S1P 5 receptor as a model and compared a set of 3 lipid ligands (sphingosine 1-phosphate [S1P], dihydro sphingosine 1-phosphate [dhS1P], and sphingosine) in 5 different functional assays: GTPγS binding, inhibition of adenylyl cyclase activity, mobilization of intracellular Ca 2+ via the FLIPR and aequorin technology, and MAP kinase (ERK1/2) activation. S1P induced agonistic responses in all except the ERK1/2 assays with EC 50 values varying by a factor of 10. Whereas dhS1P was identified as a partial agonist in the GTPγS assay, it behaved as a full agonist in all other settings. Sphingosine displayed partial agonistic activity exclusively in GTPγS binding assays. The findings suggest that assays in a given cellular background may vary significantly with respect to suitability for agonist finding and that ligands producing a response may not readily be detectable in all agonist assays. (Journal of Biomolecular Screening 2003:500-510) 
INTRODUCTION
G PROTEIN-COUPLED RECEPTORS (GPCRs) are the largest family of cell surface proteins and represent a major class of drug targets. [1] [2] [3] [4] They span the plasma membrane 7 times, and upon agonist activation, they signal via heterotrimeric G proteins composed of α, β, and γ subunits. 5 GPCRs sense extracellular stimuli as diverse as light, odorants, sugars, lipids, nucleotides, peptides, amino acids, and ions. 6 Ligand activation causes conformational changes of the receptor protein leading to heterotrimeric G protein activation, GDP-GTP exchange on the α subunit, and dissociation of GTP-bound Gα from Gβγ. 7, 8 Both Gα-GTP and Gβγ activate a plethora of signaling events within the cell. Signaling of Gα subunits is terminated by the intrinsic GTPase activity of the Gα subunit and by regulators of G protein signaling, which facilitate Gα-GTP hydrolysis and promote reassociation of the Gα-GDP-βγ complex. [9] [10] [11] [12] Methods for identifying agonists of GPCRs can take advantage of the signaling events initiated by Gα-GTP or Gβγ, with the former being more popular. The plethora of different functional assays for GPCRs imposes the question of which assay might be the most "suitable" for characterization of agonists.
To address this question, we chose the Gi-coupled human S1P 5 receptor as a model for which a set of functional assays (schematically depicted in Fig. 1 ) can be applied: 1 . After ligand binding to the receptor, endogenous heterotrimeric G proteins are activated and GDP bound to the α subunit is exchanged for GTP. GDP-GTP exchange can be monitored by using the poorly hydrolyzable radioactive analog of GTP, [ tion may already be detectable and is frequently noted as the inability of this functional assay to discriminate between full and partial agonists. [14] [15] [16] 3. An assay readout further downstream in the signaling cascade is the measurement of intracellular calcium ([Ca 2+ ] i ) mobilization. In case of the S1P 5 receptor, both Gβγ-mediated ( Fig. 1 , assay option no. 3a, aequorin technology) and Gα qi5 -, Gα ∆6qi4myr-, or Gα 16mediated phospholipase Cβ1 activation ( Fig. 1 , assay option no. 3b, fluorometric imaging plate reader [FLIPR] technology) leads to breakdown of membrane phosphatidylinositol-4,5bisphosphate (PIP 2 ), generation of diacylglycerol and inositol trisphosphate (IP 3 ), and, ultimately, release of calcium from endoplasmic reticulum stores. Signaling competent Gβγ subunits are generated upon Gα i βγ activation and Gα i -GTP/Gβγ subunit dissociation ( Fig. 1, option 3a) . 17 Gα qi5 and Gα ∆6qi4myr are Gα subunits known to channel Gi-linked receptors to the Gq-PLCβ1 pathway. [18] [19] [20] Gα 16 is a promiscuous Gα subunit known to couple many different GPCRs to activation of PLCβ1. 21 4. The exact number and nature of intermediates between an activated GPCR and extracellular regulated kinases (ERK1/2) are not completely understood; nevertheless, it can be assumed that several levels of signal amplification may be involved between the activated receptor and the activated mitogen-activated protein (MAP) kinases ( Fig. 1 , assay option no. 4). 22 A comparative analysis of the 3 lipids, sphingosine 1-phosphate (S1P), dihydro sphingosine 1-phosphate (dhS1P), and sphingosine (SPH) in various functional assays is presented. These ligands are the only available endogeneous activators of the S1P 5 receptor to date, and their affinity and efficacy in various in vitro assays has not been compared systematically yet. In this study, emphasis will be given to agonist potency, efficacy, and signal-tobackground ratio in the various assays.
MATERIALS AND METHODS

Sources of materials
S1P, dhS1P, SPH, pertussis toxin, saponin, dithiothreitol (DTT), guanosine 5′-diphosphate (GDP), guanosine 5′triphosphate (GTP), forskolin, isobutylmethylxanthine (IBMX), the RT-PCR kit, and fatty-acid-free bovine serum albumin (BSA) were from Sigma. [ 35 S]GTPγS was from NEN Life Science (Boston, MA). HEK293 and CHO-K1 cells were obtained from the American Type culture collection (ATCC, Manassas, VA); competent Escherichia coli DH5, cell culture media, and sera were from GIBCO BRL (Gaithersburg, MD); and basal Iscove and fetal calf serum (FCS) were from Biochrom (Berlin, Germany). The GC-melt PCR kit and human genomic DNA were from CLONTECH (Palo Alto, CA); oligonucleotides from MWG-Biotech AG (Ebersberg, Germany); the expression plasmid pcDNA3.1 for human S1P 5 , LipofectAMINE reagent, and E. coli MC 1061 from Invitrogen (Carlsbad, CA); and the Ca fluorescent dye Fluo4 and pluronic acid from Molecular Devices (Sunnyvale, CA). Restriction enzymes and T 4 -ligase were from New England Biolabs (Schwalbach, Germany), charcoal-stripped FCS (csFCS) was from PAN Biotech (Aidenbach, Germany); FuGENE, gentamicin, l-glutamin, and G418 solution was from Roche Diagnostics (Mannheim, Germany); the alphascreen™ cAMP assay kit was purchased from Packard BioScience (Meriden, CT), and 4′, 6diamino-2-phenylindole, was from Molecular Probes (Eugene, OR).
Molecular cloning of the human S1P 5 receptor
As the human S1P 5 (AF317676) sequence is intronless, we cloned the receptor from human genomic DNA via PCR as described previously. 23 The receptor coding sequence preceded by a Kozak consensus sequence GCC was introduced into the pcDNA3.1(+) mammalian expression vector and sequenced in both directions. The S1P 5 receptor coding sequence was excised from pcDNA3.1(+) with 5′ HindIII and 3′ NotI and ligated into the peak 8 vector (Edge Biosystems) for generation of stable cell lines.
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Murine wild-type Gα q was cloned from mouse brain by RT-PCR and inserted into the BamHI-NsiI sites of pcDNA1.1. To create the C-terminally modified Gα qi5 subunit, in which the last 5 amino acids of wt Gα q were replaced with the corresponding Gα i sequence, a 175-bp BglII-NsiI fragment was replaced, in a 2-piece ligation, with a synthetic DNA fragment, containing the desired codon changes. Construction of Gα ∆6qi4myr has been described previously. 20 All PCR-derived sequences were verified by sequencing in both directions.
Cell culture and transfection
HEK293 cells were grown in Dulbecco's modified Eagles Medium (DMEM) (with Glutamax-1, without sodium pyruvate, with 4500 mg/L glucose and pyridoxine) supplemented with 10% fetal bovine serum (FBS), penicillin-streptomycin (10,000 IU/ml-10,000 µg/ml) and 25 mM HEPES, pH 7.0. Peak stable cells were cultivated in HEK293 medium containing 400 µg/ml G418. CHO-K1 cells were cultured in basal Iscove medium supplemented with 10% FBS, penicillin-streptomycin (10,000 IU/ml-10,000 µg/ml), gentamicin (5 µg/ml), and 2 mM l-glutamin. All cells were cultivated at 37°C in a humidified 5% CO 2 incubator.
For transient transfections, 4 × 10 5 HEK293 or 2 × 10 5 CHO-K1 cells were seeded onto 35-mm dishes. About 24 h later, cells were transfected at 50% to 80% confluency with the indicated receptor (1 µg of plasmid DNA) using the FuGENE 6 transfection reagent for HEK293 or the LipofectAMINE reagent for CHO cells according to the manufacturer's instructions.
Stable expression in peak stable cells (HEK293 with G418 resistance)
4 × 10 5 PSC cells were seeded onto 35-mm dishes. After 24 h, cells were transfected at 50% confluency with 1 µg receptor or peak8 plasmid alone using the FuGENE 6 transfection reagent. Selection of transfected cells was initiated 48 h after transfection by addition of increasing concentrations of puromycin until the final concentration of 1 µg/ml was reached. G418 was removed from the culture medium when starting the selection. The stable cell lines were grown in DMEM (with Glutamax-1, without sodium pyruvate, with 4500 mg/L glucose, and pyridoxine) supplemented with 10% FBS, penicillin-streptomycin (10,000 IU/ ml-10,000 µg/ml), 25 mM HEPES, pH 7.0, and 1 µg/ml puromycin at 37°C in a 5% CO 2 /95% air atmosphere.
Membrane preparation
HEK293 cells stably expressing the indicated receptor were grown to confluence, washed with phosphate buffered saline (PBS), harvested in PBS at 4°C, and centrifuged at 1100 g at 4°C for 15 min. The pellet was resuspended in hypotonic HEPES buffer (5 mM HEPES, 1 mM EDTA) and incubated on ice for 20 min. The suspension was homogenized using a 15-ml Pyrex douncer and then centrifuged at 500 g for 10 min at 4°C. The supernatant was collected in a 2nd tube and centrifuged at 48,000 g at 4°C for 20 min. The resulting pellet was resuspended in 20 mM HEPES (pH 7.3), 1 mM EDTA, 150 mM NaCl, and 10% sucrose. Protein concentration was determined according to the method of Bradford (BioRad reagent). For pertussis toxin (PTX) treatment, cells were incubated overnight with 100 ng/ml PTX prior to membrane preparation. Protease inhibitor was added freshly to any buffer used.
[ 35 
S]GTPγS binding
Membranes and lipid-stock solutions were diluted in assay buffer (20 mM HEPES, 100 mM NaCl, 10 mM MgCl2, 1 mM EDTA, 1 mM DTT, 100 µg/ml saponin, 10 µM GDP, and fresh protease inhibitor at pH 7.4) in 96-well white Nunc plates at 25°C. Incubation was started by addition of 0.75 nM [ 35 S]GTPγS and lipids to membranes (31.25 µg/ml) and followed by a 15-min incubation period on a shaking plate. Nonspecific binding was defined using nonradioactive GTPγS (20 µM). After incubation, 50 µl of wheat germ agglutinin-coated SPA beads (30 mg/ml) were added. After a 2nd incubation step of 15 min under shaking, plates were centrifuged at 2300 g for 5 min, and radioactivitiy was measured using a Packard Top-Count. All data were normalized by subtracting nonspecific binding. For determination of the amount of bound [ 35 S]GTPγS/mg membrane, specific activity was determined and counts per minute translated into mol [ 35 S]GTPγS. Data are shown as a percentage of maximum response after subtraction of basal binding. Data represent the mean ± SEM of 3 to 4 different experiments or of 1 representative experiment.
Measurement of cAMP accumulation
1 × 10 4 HEK293 cells stably expressing the indicated receptor or vector and cultivated in medium supplemented with 10% csFCS 24 h prior to the assay were used for measurement of cAMP accumulation using the Alphascreen ® cAMP Detection Kit (Packard BioScience, Dreieich, Germany) according to the manufacturer's instructions. A total 500 µM IBMX was used for basal cAMP stimulation. Forskolin was used at a concentration of 1 µM.
Luminescence was measured with the fusion α luminometer (Canberra-Packard GmbH, Dreieich, Germany). For each experiment, 6 data points were recorded. Data are mean ± SEM of 3 to 4 independent experiments.
FLIPR assay
Calcium flux measurements were carried out essentially as described previously. 24 In brief, transiently transfected CHO-K1 cells were seeded (60.000 cells/well) in black-wall, 96-well culture plates 18 to 24 h before the functional assay. Cells were loaded with a calcium kit assay buffer (Molecular Devices) and incubated (37°C, 60 min, 5% CO 2 ). Cells were washed, agonists were added, and increases in intracellular calcium were recorded at 488 nM during 3 min with the FLIPR from Molecular Devices. Peak fluorescence counts from the 18-s to 37-s time points were used to determine agonist activity. The instrument software normalizes the fluorescent reading to give equivalent initial readings at time 0.
Cytosolic calcium measurements using CHO-G5A cells
CHO-G5A reporter cells were obtained by stable transfection of CHO-K1 cells with a chimeric aequorin-green fluorescent protein (GFP) calcium probe. 24 Cells were maintained in Ham's F12 medium supplemented with 10% FBS, penicillin/streptomycin, and 500 µg/ml geneticin.
For calcium measurements, cells were grown on white-well, clear-bottom, 96-well plates (Falcon) and transfected with 50 ng receptor cDNA/well using FuGENE 6 (Roche) according to the supplier's manual. Two days after transfection, cells were loaded with 5 µM coelenterazine h (Biotium) in calcium-free Hanks Balanced Salt Solution (HBSS) (120 mM NaCl, 5.4 mM KCl, 0.8 mM MgSO 4 , 10 mM glucose, 10 mM HEPES, pH 7.4) for 3 h at 37°C. At least 45 min prior to the experiments, the solution was replaced by HBSS containing 1.8 mM CaCl 2 . Measurements were performed with a luminometer plate reader (Luminoskan Ascent, Labsystems). Lipids were dissolved in HBSS including 0.1% fatty-acid-free BSA, injected with the built-in dispenser, and light generation by the calcium-sensitive probe was simultaneously recorded for 60 to 120 min. For quantification, kinetics were integrated using the Luminoskan Ascent software (Labsystems).
ERK in vitro kinase reactions
CHO-K1 cells were grown on 6-well plates in Ham's F12 containing 10% FCS to about 50% to 70% confluence. Transfections were done in medium with 10% csFCS with 0.75 µg receptor cDNA/well and 0.75 µg HA-ERK2 cDNA/well using FuGENE 6 according to the supplier's manual. About 24 h after transfection, cells were serum starved in Ham's F12 containing 0.1% (m/V) fatty-acid-free BSA for another 24 h and then used for experiments.
ERK activity was analyzed as previously described. 25 Briefly, serum-starved cells on 6-well plates were stimulated with the indicated ligands at 37°C followed by lysis in 0.5 ml of ice-cold buffer containing 50 mM HEPES, pH 7.2, 150 mM NaCl, 1 mM EDTA, 20 mM NaF, 2 mM sodium orthovanadate, 1% (w/v) Triton X-100, 10% (w/v) glycerol, and protease inhibitors (1 mM Pefabloc, 10 µg/ml leupeptin, and 1% Trasylol). Equal amounts of soluble fractions were subjected to immunoprecipitation with 5 µl of a polyclonal antiserum against the HA-tag and 35 µl protein Aagarose slurry for 3 h at 4°C. Resultant precipitates were washed 3 times with lysis buffer followed by 2 washes with kinase buffer (10 mM Tris, pH 7.5, 10 mM MgCl 2 ). Kinase reactions were started by addition of 25 µl kinase buffer including 200 µM ATP, 1 µCi γ[ 32 P]ATP, and 10 µg myelin basic protein (MBP). After 20 min at 30°C, reactions were stopped by addition of 20 µl SDS sample buffer and boiling for 2 min. Proteins were separated by 12% SDS polyacrylamide gel electrophoresis (SDS-PAGE), and gels were cut at the 30-kDa marker band. Upper parts were transferred onto nitrocellulose membranes and probed with 0.5 µg/ml anti-ERK2 antibodies in 5% BSA in TBS (50 mM Tris, pH 7.6, 150 mM NaCl) to check equal immunoprecipitation of HA-ERK2. Lower parts were stained with Coomassie brilliant blue R250 to monitor amounts of MBP. Substrate phosphorylation was analyzed using a PhosphoImager (BioRad, Molecular Imager FX). Western blotting of total cell lysates with monoclonal HA antibodies was performed to prove equal HA-ERK2 levels.
RESULTS
[
35
S]GTPγS binding
We initially compared S1P, dhS1P, and SPH for their ability to stimulate [ 35 S]GTPγS binding using membranes from HEK293 cells stably expressing the S1P 5 receptor. HEK293 cell lines, although expressing endogenous S1P receptors, were chosen as they exhibit negligible [ 35 S]GTPγS binding in response to S1P (data not shown). In contrast, HEK293 cells stably transfected with the S1P 5 receptor results in robust [ 35 S]GTPγS binding in response to S1P, dhS1P, and SPH with EC 50 values of 82 nM, 241 nM, and 1393 nM, respectively ( Fig. 2A , normalized data, Fig. 2B , original representative data; for comparison of all agonist data, please refer to Table 1 ). Thus, the rank order of potency and efficacy was S1P > dhS1P > SPH. These data are in good agreement with the EC 50 values for S1P and dhS1P of 43.9 and 124.4 nM at the human S1P 5 receptor reported by Im and colleagues. 26 [ 35 S]GTPγS binding in response to the respective lipids was totally abolished in membranes from cells pretreated with PTX overnight (data not shown), suggesting the involvement of Gα i/o proteins.
cAMP accumulation
To compare the rank order of potencies and relative efficacies of the 3 lipids in a cAMP assay where theoretically more signal amplification exists, HEK293 cells stably expressing the S1P 5 receptor were tested for inhibition of forskolin-stimulated adenylyl cyclase activity. S1P and dhS1P treatment resulted in about 40% inhibition of forskolin-driven cAMP rises with similar potency and efficacy ( Fig. 3 , S1P, EC 50 = 183 nM; dhS1P, EC 50 = 363 nM). Although partial agonists as determined by [ 35 S]GTPγS binding assays often show up as full agonists in cAMP assays, SPH was not active in concentrations up to 100 µM (Fig. 3 ). All 3 lipids did not evoke inhibition of forskolin-stimulated adenylyl cyclase in mocktransfected control cells ( Fig. 3, open symbols) .
Calcium-based FLIPR assay
To compare agonist activities of S1P, dhS1P, and SPH in a calcium-based FLIPR assay, CHO cells were transiently cotransfected with the cDNAs for the S1P 5 receptor and the chimeric G proteins Gα qi5 , Gα ∆6qi4myr , or Gα 16 (Fig. 4) . All 3 subunits fa-
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cilitate GPCR signaling through the phospholipase Cβ1/IP 3 /Ca 2+ pathway. Gα qi5 20 and Gα ∆6qi4myr 19,20 are particularly useful to channel Gi-linked receptors to the Gq-pathway; Gα 16 couples a wide range of Gi-and Gs-linked receptors to activation of PLCβ1. 19, 21, 27 CHO-K1 cells transfected with empty vector DNA or chimeric Gα qi5 alone were unresponsive to S1P, dHS1P ( Fig. 4A,B ,C,D) or SPH (data not shown). In contrast, CHO-K1 cells transfected with both the S1P 5 receptor and Gα qi5 were responsive to S1P (EC 50 = 300 nM; Fig. 4C ) and dhS1P (EC 50 = 260 nM; Fig. 4D ) but not to SPH (data not shown). Interestingly, CHO cells transfected with Gα ∆6qi4myr and Gα 16 and unlike Gα qi5 transfected cells significantly responded to S1P and dhS1P ( Fig. 4E ,F,G,H), suggesting that they potently link endogeneous lipid receptors to the PLCβ pathway. Cotransfection of the S1P 5 receptor and either promiscuous G protein did not cause a significant leftward shift of the S1P-mediated calcium mobilization or a significant increase of the signal-tonoise window as to allow for utilization in agonist screening assays ( Fig. 4E,F,G,H) . SPH did not evoke any agonistic response in all G protein-expressing cell lines, nor did it yield a specific signal when the S1P 5 receptor was coexpressed (data not shown).
Calcium-based aequorin assay
Many Gi-coupled receptors possess the ability to stimulate βγsensitive PLCβ isoforms through the βγ subunits released upon activation of Gα i . [28] [29] [30] βγ-mediated PLCβ activation often generates calcium peaks that are not sufficiently high as to be detected with the FLIPR technology. In line with this observation is the finding that S1P 5 receptor-expressing CHO cells when challenged with S1P or dhS1P do not generate measurable calcium responses (Fig. 4A,B) . As the aequorin-based calcium assays display higher sensitivity than the FLIPR assays, we were tempted to functionally analyze the S1P 5 receptor-mediated stimulation of PLCβ via the βγ subunit complex. To this end, CHO cells expressing a GFPaequorin fusion protein were transiently transfected with the S1P 5 receptor, and calcium responses to S1P, dhS1P, and SPH were quantified. In contrast to the FLIPR assays and in accordance with the high sensitivity reported for this technology, S1P and dhS1P induced significant responses in vector transfected control cells (compare Fig. 4A,B with Fig. 5A,B) , reflecting endogenous expression of lipid receptors. Surprisingly, S1P but not dhS1P was able to generate a significant signal beyond background in cells cotransfected with the S1P 5 receptor and the GFP-aequorin fusion protein (Fig. 5A,B) . For S1P, the PLCβ response had an EC 50 of 2200 nM in vector transfected control cells and 1100 nM in S1P 5 transfected cells (Fig. 5A ). SPH neither showed any background response in vector transfected cells nor evoked a specific signal in S1P 5 receptor transfected cells (Fig. 5C ).
ERK phosphorylation
We have recently shown that S1P 5 receptor-mediated inhibition of ERK phosphorylation is constitutive. 31 To test whether the ERK assay is suitable for identification of S1P 5 receptor agonists, we initially tested S1P for its ability to inhibit ERK1/2. As displayed in Figure 6 , S1P failed to enhance the intrinsic S1P 5 receptormediated ERK1/2 inhibition. As the endogenous, high-affinity ligand S1P turned out to be ineffective, we did not carry out ERK assays in the presence of the other 2 lipids. It has to be noted that inhibition of ERK1/2 phosphorylation was the only assay in which constitutive activity of the S1P 5 receptor precluded assessment of agonism by the respective lipids.
DISCUSSION
In recent years, functional assays have gained considerable popularity over the classical ligand-binding assays for screening of agonists and antagonists. Binding assays simply determine the re- Functional response of the S1P 5 receptor to S1P, dhS1P, and SPH in a functional aequorin calcium assay. CHO-K1 cells expressing the chimeric aequorin-green fluorescent protein calcium reporter were transiently transfected with the S1P 5 receptor and tested for its responsiveness to S1P (A), dhS1P (B), and SPH (C). Data points represent the mean ± SEM for duplicates of 3 independent experiments. lationship between the concentration of a ligand and the resulting ligand receptor complexes. Functional assays translate extracellular signals into intracellular responses, thus allowing to obtain a concentration-response relationship. Functional assays are far more complex as interaction of ligand with receptors initiates communication with other membrane and cytosolic effector proteins. There are several assay possibilities to detect activation of those effectors such as GTPγS binding, 2nd messenger and calcium-based assays often including promiscuous or chimeric G proteins, MAP kinase assays, and so forth. In general, functional assays monitor endpoints that are downstream of GPCR activation: GTPγS binding is the 1st downstream event, 2nd messenger generation, calcium mobilization or activation of MAP kinase pathways are well downstream of GPCR activation with several potential signal amplification steps in between and thus potentially higher signals but also potentially higher signal-to-background ratios.
It is a priori not clear whether in a given cellular background the various functional assays are interchangeable and whether signal amplification downstream of receptor/G protein interaction might lead to an increase or decrease of assay sensitivity. It is generally a concern that detection of partial agonists of Gi-coupled receptors is hampered in inhibitory cyclic AMP assays but not in GTPγS binding assays. [14] [15] [16] 32 Intracellular signal amplification between the upstream G protein and the downstream target adenylyl cyclase has been regarded as responsible for this observation. 16 Thus, binding of GTPγS in membrane preparations is probably the most sensitive method to distinguish between full and partial agonists. Our GTPγS assay identified S1P, dhS1P, and SPH as agonists, with SPH being clearly the least potent end efficacious ligand. Given that partial agonists in GTPγS assays often appear as full and/or higher potency agonists in cAMP assays, 16, 33 it is even more surprising that SPH only displayed agonistic activity in GTPγS assays but was inactive in all other functional assays. SPH stimulation of GTPγS binding was completely blocked in the presence of PTX, suggesting a Gα i/o -mediated response. We can exclude that the agonistic effects of SPH are due to phosphorylation by sphingosine kinase (SPHK) and thus production of S1P for the following reasons: 1) SPHK exerts negligible activity in membranes prepared from HEK293 cells (20 pmol/min/mg protein), 2) the membrane preparation used for a GTPγS assay exhibits only 18% of the total SPHK activity, and 3) ATP levels in such membrane preparations are far below the required concentration as to allow for conversion of SPH to S1P by SPHK. 34 Recently, the immune modulator FTY720-P, similar in structure to S1P, has been shown to activate sphingosine 1-phosphate receptors S1P 1,3,4,5 with high and comparable affinity in GTPγS binding assays. 32 The nonphosphorylated alcohol FTY720 was 30 times less potent on the S1P 4 receptor but not efficacious at the S1P 1,3,5 receptors (data not shown in ref. 32) . These data suggest that some but not all S1P receptor subtypes may be sensitive to modulation with the nonphosphorylated alcohol congeners of the respective agonist lipids. In this aspect, the S1P 5 receptor may re-semble the S1P 4 receptor in that it is activated by both a phosphorylated and a nonphosphorylated lipid, albeit with different potencies.
It is interesting to note that the GTPγS assay is the only assay in which the partial agonist nature of dhS1P becomes "visible" in addition to a slightly lower potency as compared with that for S1P. In contrast, none of the other assays allowed for any distinction between S1P and dhS1P. These data are in good agreement with several published reports showing that the GTPγS assay is the most suitable for discriminating potency and efficacy of agonist ligands. [14] [15] [16] 33 Indeed, the results of the GTPγS assay rather seem to reflect the in vivo situation: In primary rat aortic smooth muscle cells, S1P and dhS1P inhibited platelet-derived growth factorstimulated chemotaxis and Rac activation, but dhS1P was less potent and efficacious than S1P. 35 We made the unexpected observation that the S1P 5 receptor upon stimulation with S1P or dhS1P was able to stimulate PLC via Gα qi5 with an EC 50 value of 300 nM, comparable to that observed for Gα i -mediated inhibition of adenylyl cyclase or Gα i -mediated stimulation of GTPγS binding. Frequently, however, Gi-coupled receptors that are forced to signal through PLCβ by using a chimeric or promiscuous G protein display lower potency for agonists in this artificial signal transduction system. For example, in the case of the C5a receptor, Gα 16 -mediated stimulation of PLCβ required much higher concentrations of C5a than inhibition of adenylyl cyclase. 36, 37 The µ, κ, and δ opioid receptors stimulate PLCβ via Gα 16 with EC 50 values about 50 times higher than those required for Gα i -mediated inhibition of adenylyl cyclase. 29 The neuropeptide FF receptor HLWAR77 requires about 10-fold higher concentrations of NPFF for Gα qi5 -mediated stimulation of PLCβ as compared with that for inhibition of adenylyl cyclase. 38 Furthermore, the somatostatin SSTR1 receptor is linked much more efficiently to inhibition of adenylyl cyclase 39, 40 as compared with stimulation of PLCβ through a chimeric Gα q/i protein or Gα 16 . 19, 20 A few cases, however, exist in which affinity shifts for natural and artificial coupling do not occur as the muscarinic M2 receptor is reported to couple with equal potency to inhibition of adenylyl cyclase and Gα 16 -mediated stimulation of PLCβ. 21 The β2 adrenergic receptor is another example for equipotent coupling to the natural Gα s -mediated cAMP production and to the artificial stimulation of PLCβ via Gα 16 . 21 The melanin concentrating hormone (MCH) receptor induces intracellular calcium mobilization when coexpressed with a chimeric Gα q/i protein with equal potency as it inhibits forskolin-stimulated adenylyl cyclase upon challenge with MCH. 41 It is so far not predictable how receptors perform in terms of agonist potency in screening systems based on the natural or an artificial signal transduction pathway. If agonist potencies are compared in both natural and artificial coupling systems and do not yield major potency shifts, both assays tend to be regarded as interchangeable. There is one caveat, however, that we would like to highlight and that is based on recent findings on the neurokinin NK 1 receptor. The NK 1 receptor couples to Gα s and Gα q and the molecular phenotype of this receptor; that is, its way to interact with agonist ligands is determined by the species of Gα accessible to this receptor. 42 In other words, the Gα subunit may determine microconformations of the receptor, and these in turn may influence the agonists that will be identified in a screening assay. Under the prerequisite that there is no substantial overlap between microconformations induced by the natural as compared with an artificial G protein, the nature of agonist ligands may differ substantially. In case of the S1P 5 receptor, there definitely is an overlap of such microconformations as S1P is identified in cAMP and GTPγS assays reflecting the natural coupling as well as in calcium assays with a chimeric G protein. It cannot be excluded, however, that an agonist screening identifies a range of compounds with activity in one but not the other assay or at least with very different potencies or efficacies. The very sensitive aequorin-based calcium assay that is able to measure βγ-mediated calcium responses upon Gα i activation represents an alternative to the FLIPR assay in that it does not depend on the cotransfection of a receptor and a chimeric or promiscuous G protein. 43 We used a chimeric GFP-aequorin as a bioluminescent calcium reporter, taking advantage of the efficient chemoluminescence resonance energy transfer from calciumbound aequorin to GFP. 24 In accordance with the high sensitivity of this calcium reporter and in contrast to the fluorescence-based FLIPR assay, S1P and dhS1P treatment resulted in robust calcium signals in vector transfected control cells (Fig. 5A,B) . Surprisingly, only S1P but not dhS1P was able to generate a significant calcium response beyond background (Fig. 5A,B) . Although detecting activation of the natural pathway of the S1P 5 receptor, S1P stimulation of calcium mobilization had an EC 50 of 1100 nM, which is about 10-fold higher than the EC 50 in GTPγS binding or cAMP assays. These results are in line with previous reports showing that βγ-mediated PLCβ activation by Gi-coupled receptors requires quite high concentrations of agonists 29, 30, 44 and that it is not always advantageous to detect activation of the native signaling pathway. It should be noted, however, that some Gi-linked receptors such as the S1P 4 45 or the adenosine A 3 receptor 46 elicit βγ-mediated calcium responses when stimulated with agonists with nanomolar EC 50 values corresponding to those in whole-cell cAMP assays.
Another disadvantage of the highly sensitive aequorin system shall be illustrated: Whereas CHO cell lines can be easily used as expression systems for S1P receptors in FLIPR assays, the high endogenous background responses to S1P of vector transfected cells in aequorin assays may preclude their utilization for agonist screenings. Notwithstanding, comparable background problems occur in FLIPR assays when highly sensitive promiscuous G proteins are expressed in the cells. Whereas Gα qi5 is well suited for generating calcium responses to S1P in S1P 5 receptor coexpression studies (Fig. 4C,D) , the highly sensitive Gα ∆6qi4myr or Gα 16 potently link several endogenous receptors to PLCβ activation such that agonist potency or efficacy is hardly affected on coexpression of the S1P 5 receptor (Fig. 4E,F,G,H) .
Inhibition of ERK1/2 in S1P 5 receptor-expressing cells did not allow detection of any agonistic effect in response to S1P. Agonistindependent activity of the S1P 5 receptor might have caused this as the S1P 5 receptor intrinsically inhibits ERK1/2 phosphorylation in the absence of agonist and, obviously, ERK1/2 inhibition cannot be further augmented in the presence of S1P (Fig. 6 ). It is interesting to note that agonist-independent activity of the S1P 5 receptor allows for additional receptor activation in the 2nd messenger or calcium-based assays but not in the ERK1/2 assays. It may be speculated that activation of MAP kinases well down the GPCR signaling cascade is maximal even in the absence of agonist due to signal amplification by the many intermediate signaling molecules. Alternatively, the S1P 5 receptor may adopt an active conformation that directs the receptor to the MAP kinase signaling pathway but not, or to a lesser extent, to other intracellular responses. This hypothesis is based on the observation that constitutively active receptors differentially activate different effector pathways. 31, 47 It is supported by the model that receptors adopt a number of (micro) conformations, many of which induce one or more pharmacological activities 48 and that different agonists enrich different receptoractive states leading to different signaling to G proteins, a phenomenon termed agonist trafficking of receptor responses. [49] [50] [51] In summary, we have shown that determination of agonist potencies and efficacies in artificial receptor and/or G protein overexpression systems may vary significantly and that the level of signaling cascade that is analyzed indeed has an impact on the quantification of agonist properties. We therefore recommend against exclusive reliance on a single functional agonist assay, but rather to analyze agonist activities in more than one cellular background using a readout as close as possible to the nucleotideexchange event within the G protein α subunit. This seems to be particularly important when analyzing receptors with a constitutively active phenotype.
